ImmunityBio, Inc.
No SEC Form 4 filings for $IBRX in the last 30 days.
See all $IBRX insider activity →Vanguard Capital Management increased its stake in Sellas Life Sciences (SLS) by 9.3% to 8.23 million shares and held 15.69 million shares of ImmunityBio (IBRX) valued at $137.4 million, according to June 30 filings. SLS009 Phase 2 enrolled 28 of 80 patients, initial data due Q4. IBRX reported record Anktiva revenue and seeks label expansion.
Simply Wall St reports ImmunityBio (IBRX) received UAE marketing authorization for ANKTIVA in BCG unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. The stock closed at $7.64, up 4.37% on the day and 6.56% over a week. It cites fair value estimates of $13 and $46.07, with premium sales multiples and ongoing losses.
ImmunityBio (IBRX) is in focus ahead of founder Patrick Soon-Shiong’s AUA 2026 talk, where he plans to discuss challenges for papillary bladder cancer patients, including ongoing BCG shortages. The company says Merck (MRK) is the only global BCG supplier and that its Anktiva is approved only with BCG. IBRX shares were down about 3% Friday.
Over the past 7 days, alphai's AI scored 2 news stories mentioning IBRX (ImmunityBio, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent IBRX coverage spans financial news, regulation and market movers.
The combination of continued institutional support and a dated FDA decision window can keep the stock bid, but the FDA outcome is still future.
UAE approval is a tangible regulatory milestone that can support incremental revenue expectations, but the article frames the stock as already priced for aggressive growth.
Near-term catalyst is the Saturday AUA discussion, but the article does not add a new FDA decision or new clinical/regulatory datapoint.
The filing adds a concrete FDA regulatory timeline while confirming strong commercial momentum, which can re-rate near-term probability-weighted outcomes for ANKTIVA.
UAE approval broadens ANKTIVA’s label and supports incremental commercial optionality in bladder cancer and checkpoint-refractory NSCLC.
alphai scores every news story that mentions IBRX with an AI model for sentiment and relevance, and aggregates insider trades from ImmunityBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vanguard Capital Management increased its stake in Sellas Life Sciences (SLS) by 9.3% to 8.23 million shares and held 15.69 million shares of ImmunityBio (IBRX) valued at $137.4 million, according to June 30 filings. SLS009 Phase 2 enrolled 28 of 80 patients, initial data due Q4. IBRX reported record Anktiva revenue and seeks label expansion.
7 min readSimply Wall St reports ImmunityBio (IBRX) received UAE marketing authorization for ANKTIVA in BCG unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. The stock closed at $7.64, up 4.37% on the day and 6.56% over a week. It cites fair value estimates of $13 and $46.07, with premium sales multiples and ongoing losses.
6 min readImmunityBio (IBRX) is in focus ahead of founder Patrick Soon-Shiong’s AUA 2026 talk, where he plans to discuss challenges for papillary bladder cancer patients, including ongoing BCG shortages. The company says Merck (MRK) is the only global BCG supplier and that its Anktiva is approved only with BCG. IBRX shares were down about 3% Friday.
4 min readImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ibrx-202684x8kexhibit991.htm EX-99.1 Document EXHIBIT 99.1 ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million • Q2 2026 net product revenue of $50.7 million, up 92% year-over-year a
6 min readEmirates Drug Establishment approved ImmunityBio’s (NASDAQ:IBRX) ANKTIVA in the UAE for BCG-unresponsive non-muscle invasive bladder cancer, allowing a 0.4 mg intravesical dose with BCG across the full NMIBC spectrum. It also approved a 1.2 mg subcutaneous dose with checkpoint inhibitors for metastatic NSCLC. QUILT-3.032 reported 71% CIS complete response; QUILT-3.055 median OS was 14.6 months. IBRX shares rose 5.49% to $7.20.
3 min readImmunityBio (NASDAQ:IBRX) shares rose about 7.5% after the UAE granted marketing authorization for ANKTIVA. Approval covers NMIBC with BCG (based on QUILT-3.032) and metastatic NSCLC with immune checkpoint inhibitors (QULT-3.055). The UAE authorization expands ANKTIVA’s regulatory footprint to 34 countries.
4 min readU.S. stock futures were higher in early Thursday trade as investors digested tech earnings, fresh military action in the Middle East, an increasingly divided Federal Reserve and crucial inflation data due later today. Microsoft and Meta earnings highlighted that AI infrastructure spending will continue at an enormous pace. However, investors cheered Microsoft’s reassurance on its $35.8B capex efficiency, and punished Meta’s elevated FY26 capex outlook.
6 min readU.S. stock index futures rose overnight after the Fed held benchmark rates steady, though investors cited elevated inflation concerns. The Dow, S&P 500 and Nasdaq fell on Wednesday. Microsoft earnings beat and shares rose, while Meta and Qualcomm declined. Oil rose on U.S.-Iran retaliation. ImmunityBio jumped on UAE approval for Anktiva.
7 min readCohen Cheryl sold 131,210 shares of ImmunityBio, Inc. (IBRX) at $9.50 ($1.25M total) on 2026-07-02 under a Rule 10b5-1 trading plan.
1 min readSelecky Christobel sold 159,478 shares of ImmunityBio, Inc. (IBRX) at $9.02 ($1.44M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min read
